

**Freedom of Information Act 2000 - Request Reference FoI/22/540**

**Breast Cancer Treatments**

**Information Requested:**

1. In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:
  - Abemaciclib monotherapy
  - Aromatase inhibitor monotherapy (e.g. anastrozole, exemestane, letrozole)
  - Tamoxifen monotherapy
  - Abemaciclib + Tamoxifen
2. In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:
  - Abemaciclib + Aromatase inhibitor (e.g. anastrozole, exemestane, letrozole)
  - Taxane and/or Anthracycline (monotherapy or in combination)
  - Any other active systemic anti-cancer therapy
3. How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
  - Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
  - Atezolizumab +Nab-paclitaxel/Paclitaxel
  - Pembrolizumab
  - Sacituzumab Govitecan
  - Parp Inhibitors (Olaparib/Talazoparib)
  - Eribulin as a single agent or in combination
  - Capecitabine as a single agent
  - Platinum (e.g. carboplatin or cisplatin) as a single agent
  - Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
  - Taxane and/or Anthracycline in combination
  - Any other active systemic anti-cancer therapy

**Response details:**

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that these treatments are provided by Velindre Cancer Centre, please see their contact details below:

[foi.vunhst@wales.nhs.uk](mailto:foi.vunhst@wales.nhs.uk)

Or,

Velindre NHS Trust Headquarters.  
Unit 2 Charnwood Court,  
Parc Nantgarw,  
Nantgarw,

Cardiff.  
CF15 7QZ